Assessment and management of Chagas disease: a comprehensive analysis
Abstract
The protozoan Trypanosoma cruzi is the cause of Chagas disease, a serious but often ignored topical illness that mostly affects people in Latin America. Triatomine bugs are the vector of transmission, and the illness can progress through acute and chronic phases, the latter of which may cause serious neurological, gastrointestinal, or cardiac problems. Chagas disease is still a major worldwide health concern despite tremendous progress in diagnosis and treatment because of poor control measures in endemic areas, lack of knowledge, and restricted access to healthcare. This review article gives a summary of what is now known about Chagas disease, including its pathogenesis, clinical presentation, epidemiology, and diagnostic methods. It also examines the current therapy choices, emphasizing the difficulties associated with pharmacological effectiveness, side effects, and the requirement for novel treatment alternatives. The essay also covers the global spread of Chagas disease and how increased travel patterns have contributed to its growth, as well as current developments in monitoring systems and vector control techniques. In order to combat the rising incidence of Chagas disease globally, the study also emphasizes current studies into new treatment drugs and vaccine development. This review article gives a summary of what is now known about Chagas disease, including its pathogenesis, clinical presentation, epidemiology, and diagnostic methods. It also examines the current…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.